Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRT 2359

X
Drug Profile

MRT 2359

Alternative Names: MRT-2359

Latest Information Update: 10 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monte Rosa Therapeutics
  • Class Antineoplastics; Carbamates; Ethers; Fluorobenzenes; Isoindoles; Ketones; Piperidines; Small molecules
  • Mechanism of Action Peptide-chain-release factor 3 degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 08 Jan 2024 MRT 2359 receives Fast Track designation for Small cell lung cancer [PO] (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA
  • 03 Nov 2023 Chemical structure information added
  • 17 Oct 2023 Interim efficacy, adverse events and pharmacodynamics data from a phase I/II trial in Neuroendocrine tumours, Non-small cell lung cancer, Small cell lung cancer, Solid tumours and Lymphoma released by Monte Rosa Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top